Ionenkanalerkrankungen: Schnittstellen zwischen Kardiomyopathien und malignen Arrhythmien

Schlüsselwörter

plötzlicher Herztod - Kardiomyopathie - primär elektrische Erkrankung - Brugada-Syndrom - Short-QT–Syndrom - Long-QT-Syndrom

Keywords

sudden cardiac death - cardiomyopathy - channelopathy - Brugada syndrome - short QT syndrome - long QT syndrome - CPVT

• Literatur

• 1 Ackerman MJ, Priori SG, Willems S et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2011; 13: 1077-1109
• 2 Antzelevitch C, Pollevick GD, Cordeiro JM et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115: 442-449
• 3 Antzelevitch C, Shimizu W, Yan GX et al. Cellular basis for QT dispersion. J Electrocardiol 1998; 30 (Suppl. 01) 168-175
• 4 Baba S, Dun W, Cabo C et al. Remodeling in cells from different regions of the reentrant circuit during ventricular tachycardia. Circulation 2005; 112: 2386-2396
• 5 Benito B, Sarkozy A, Mont L et al. Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol 2008; 52: 1567-1573
• 6 Bhuiyan ZA, van den Berg MP, van Tintelen JP et al. Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation 2007; 116: 1569-1576
• 7 Blaich A, Pahlavan S, Tian Q et al. Mutation of the calmodulin binding motif IQ of the L-type Ca(v)1.2 Ca2+ channel to EQ induces dilated cardiomyopathy and death. J Biol Chem 2012; 287: 22616-22625
• 8 Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20: 1391-1396
• 9 Brugada R, Hong K, Dumaine R et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109: 30-35
• 10 Corrado D, Basso C, Buja G et al. Right bundle branch block, right precordial st-segment elevation, and sudden death in young people. Circulation 2001; 103: 710-717
• 11 Cronk LB, Ye B, Kaku T et al. Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm 2007; 4: 161-166
• 12 Cunha SR, Hund TJ, Hashemi S et al. Defects in ankyrin-based membrane protein targeting pathways underlie atrial fibrillation. Circulation 2011; 124: 1212-1222
• 13 Cunha SR, Mohler PJ. Ankyrin protein networks in membrane formation and stabilization. J Cell Mol Med 2009; 13: 4364-4376
• 14 Curran ME, Splawski I, Timothy KW et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803
• 15 Chen L, Marquardt ML, Tester DJ et al. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci USA 2007; 104: 20990-20995
• 16 Chen Q, Kirsch GE, Zhang D et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293-296
• 17 Ellison GM, Torella D, Karakikes I et al. Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells. J Biol Chem 2007; 282: 11397-11409
• 18 Frustaci A, Priori SG, Pieroni M et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation 2005; 112: 3680-3687
• 19 Frustaci A, Russo MA, Chimenti C. Structural myocardial abnormalities in asymptomatic family members with Brugada syndrome and SCN5A gene mutation. Eur Heart J 2009; 30: 1763
• 20 Gaita F, Giustetto C, Bianchi F et al. Short QT Syndrome: a familial cause of sudden death. Circulation 2003; 108: 965-970
• 21 Giustetto C, Di Monte F, Wolpert C et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006; 27: 2440-2447
• 22 Giustetto C, Schimpf R, Mazzanti A et al. Long-term follow-up of patients with short QT syndrome. JAAC 2011; 58: 587-595
• 23 Goldenberg I, Horr S, Moss AJ et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011; 57: 51-59
• 24 Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is „normal“. J Cardiovasc Electrophysiol 2006; 17: 333-336
• 25 Gorgels AP, Gijsbers C, de Vreede-Swagemakers J et al. Out-of-hospital cardiac arrest – the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003; 24: 1204-1209
• 26 Gussak I, Brugada P, Brugada J et al. Idiopathic short QT interval: a new clinical syndrome?. Cardiology 2000; 94: 99-102
• 27 Haugaa KH, Edvardsen T, Leren TP et al. Left ventricular mechanical dispersion by tissue Doppler imaging: a novel approach for identifying high-risk individuals with long QT syndrome. Eur Heart J 2009; 30: 330-337
• 28 Haugaa KH, Johnson JN, Bos JM et al. Subclinical Cardiomyopathy and Long QT Syndrome: An Echocardiographic Observation. Congenit Heart Dis 2012; epub.
• 29 Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957; 54: 59-68
• 30 Keating M, Atkinson D, Dunn C et al. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science 1991; 252: 704-706
• 31 Lahat H, Pras E, Olender T et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69: 1378-1384
• 32 Landstrom AP, Ackerman MJ. Beyond the cardiac myofilament: hypertrophic cardiomyopathy- associated mutations in genes that encode calcium-handling proteins. Curr Mol Med 2012; 12: 507-518
• 33 Lanner JT. Ryanodine receptor physiology and its role in disease. Adv Exp Med Biol 2012; 740: 217-234
• 34 Le Scouarnec S, Bhasin N, Vieyres C et al. Dysfunction in ankyrin-B-dependent ion channel and transporter targeting causes human sinus node disease. Proc Natl Acad Sci U S A 2008; 105: 15617-15622
• 35 Leenhardt A, Lucet V, Denjoy I et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512-1519
• 36 Liu X, Betzenhauser MJ, Reiken S et al. Role of leaky neuronal ryanodine receptors in stress-induced cognitive dysfunction. Cell 2012; 150: 1055-1067
• 37 Loewel H, Engel S, Hörmann A et al. Acute myocardial infarction and sudden cardiac death from an epidemiological point of view. Intensivmed 1999; 36: 652-661
• 38 Martini B, Nava A, Thiene G et al. Ventricular fibrillation without apparent heart disease: description of six cases. Am Heart J 1989; 118: 1203-1209
• 39 Meissner FL. Taubstummheit und Taubstummenbildung: Beobachtungen und Erfahrungen, nebst einer Geschichte der Leipziger Taubstummen-Anstalt. In, Taubstummheit, Ohr-und Gehoerkrankheiten. Leipzig; Heidelberg: Winter; 1856: 387
• 40 Mohler PJ, Rivolta I, Napolitano C et al. Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. Proc Natl Acad Sci USA 2004; 101: 17533-17538
• 41 Mohler PJ, Schott JJ, Gramolini AO et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421: 634-639
• 42 Moss AJ, Zareba W, Benhorin J et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92: 2929-2934
• 43 Moss AJ. Clinical management of patients with the long QT syndrome: drugs, devices, and gene-specific therapy. Pacing Clin Electrophysiol 1997; 20: 2058-2060
• 44 Nador F, Beria G, De Ferrari GM et al. Unsuspected echocardiographic abnormality in the long QT syndrome. Diagnostic, prognostic, and pathogenetic implications. Circulation 1991; 84: 1530-1542
• 45 Napolitano C, Priori SG, Schwartz PJ et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. Jama 2005; 294: 2975-2980
• 46 Papavassiliu T, Wolpert C, Fluchter S et al. Magnetic resonance imaging findings in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004; 15: 1133-1138
• 47 Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res 2011; 108: 871-883
• 48 Priori SG, Napolitano C, Gasparini M et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105: 1342-1347
• 49 Priori SG, Napolitano C, Tiso N et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103: 196-200
• 50 Rautaharju PM, Surawicz B, Gettes LS et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 2009; 119: e241-250
• 51 Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002; 54: 431-467
• 52 Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare in eta` pediatrica. Clin Pediatr (Bologna) 1963; 45: 656-657
• 53 Schimpf R, Meinhardt J, Borggrefe M et al. Catecholaminergic ventricular tachycardia and midventricular Takotsubo cardiomyopathy: A novel association?. Herzschrittmacherther Elektrophysiol 2013; in press
• 54 Schwartz PJ, Spazzolini C, Crotti L et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation 2006; 113: 783-790
• 55 Schwartz PJ, Stramba-Badiale M, Crotti L et al. Prevalence of the congenital long-QT syndrome. Circulation 2009; 120: 1761-1767
• 56 Swan H, Piippo K, Viitasalo M et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999; 34: 2035-2042
• 57 Tang Y, Tian X, Wang R et al. Abnormal termination of Ca2+ release is a common defect of RyR2 mutations associated with cardiomyopathies. Circ Res 2012; 110: 968-977
• 58 Ueda K, Valdivia C, Medeiros-Domingo A et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci U S A 2008; 105: 9355-9360
• 59 Vatta M, Ackerman MJ, Ye B et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006; 114: 2104-2112
• 60 Ward OC. A New Familial Cardiac Syndrome in Children. J Ir Med Assoc 1964; 54: 103-106
• 61 Woodman SE, Park DS, Cohen AW et al. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 2002; 277: 38988-38997
• 62 Zumhagen S, Spieker T, Rolinck J et al. Absence of pathognomonic or inflammatory patterns in cardiac biopsies from patients with Brugada syndrome. Circ Arrhythm Electrophysiol 2009; 2: 16-23
• 63 Bayes de Luna A, Brugada J, Baranchuk A et al. Current electrographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol 2012; 45: 433-442
• 64 Hinterseer M, Beckmann BM, Thomsen MB et al. Relation of increased short-term variability of QT interval to congenital long-QT syndrome. Am J Cardiol 2009; 103: 1244-1248
• 65 Lin JW, Wyszynski M, Madhaven R et al. Yotiao, a novel protein of neuromuscular junction and brain that interacts specific splice variants of NMDA receptor subunit NR1. J Neurosci 1998; 18: 2017-2027
• 66 Veltmann C, Schimpf R, Echternach C et al. A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J 2006; 27: 2544-2552